Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUBY-I: 3-DAA Regimen in HCV with Severe Renal Impairment
NCT02207088Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2014
- Primary completion
- Dec 2016
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 3 trial of ombitasvir, paritaprevir, ritonavir, dasabuvir in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Sep 2014; status: completed.
02
Drugs
ombitasvirparitaprevirritonavirdasabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02207088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02207088.